MA1-43012

antibody from Invitrogen Antibodies

Targeting: F9 FIX

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Radioimmunoassay (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-43012

Provider

Invitrogen Antibodies

Product name

Factor IX Monoclonal Antibody (5041)

Antibody type

Monoclonal

Antigen

Other

Description

MA1-43012 detects Factor IX in human samples, human factor Ixa and the heavy chain of human factor IX and IXa. MA1-43012 has successfully been used in radioimmune assays, ELISA, Western blot and immunohistochemistry applications. MA1-43012 was derived from human factor IX.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

5041

Vial size

100 µg

Concentration

9.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins.

Pavani G, Laurent M, Fabiano A, Cantelli E, Sakkal A, Corre G, Lenting PJ, Concordet JP, Toueille M, Miccio A, Amendola M
Nature communications 2020 Jul 29;11(1):3778

---

Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.

Collaud F, Bortolussi G, Guianvarc'h L, Aronson SJ, Bordet T, Veron P, Charles S, Vidal P, Sola MS, Rundwasser S, Dufour DG, Lacoste F, Luc C, Wittenberghe LV, Martin S, Le Bec C, Bosma PJ, Muro AF, Ronzitti G, Hebben M, Mingozzi F
Molecular therapy. Methods & clinical development 2019 Mar 15;12:157-174

---

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.

Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, Vignaud A, van Wittenberghe L, Manni G, Christophe O, Fallarino F, Roy C, Michaud A, Ilyinskii P, Kishimoto TK, Mingozzi F
Nature communications 2018 Oct 5;9(1):4098

---

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.

Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, Vignaud A, Collaud F, Charles S, Simon Sola M, Jouen F, Boyer O, Mingozzi F
Molecular therapy. Methods & clinical development 2018 Jun 15;9:119-129

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 F9 KI into the alpha-globin locus results in expression and secretion of functional enzyme. a AAV6 donor used for KI experiments of FIX Padua. b FIX KI efficiency in HUDEP-2 cells was measured by flow cytometry (light green) or ddPCR specific for on-target integration (dark green) before and after sorting ( n = 1). c Quantification of FIX mRNA in KI HUDEP-2 upon differentiation (mean +- SD, n = 2 undifferentiated, n = 3 differentiated). d Quantification of FIX secretion in medium of HUDEP-2 clones ( n = 28) with monoallelic or biallelic KI (ELISA), as detected by on target ddPCR analysis (AAV-genome junction amplification). Lines represent median. e KI efficiency in HSPCs at day 9 of erythroid differentiation. Lines represent mean ( n = 4). f , g FIX expression during HSPC differentiation at RNA ( f , qPCR; n = 2 day 9; n = 4 day 12) and protein level ( g , ELISA on supernatants, n = 3 day 7; n = 4 day 9 and 12; 3 donors). Bars represent mean +- SD. h Comparison of FIX antigen (ELISA) and activity (aPTT) in supernatants of KI HSPCs (mean; n = 2). i , j Comparison of FIX RNA at day 9 and 12 of erythroid differentiation ( i ) and protein ( j ) in KI HSPCs (AAV + RNP) vs HSPCs transduced with an erythroid-specific lentiviral vector (LvEry FIX). Bars represent mean (** p = 0.003 t -test Holm-Sidak correction for RNA at day 12; p = 0.08 for protein, n = 2). k Integration pattern in single BFU-E (2 donors): no integration (0), monoallelic (1) and biallelic KI (2). Source dat